| Authors: |
Stenehjem DD; Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA Huntsman Cancer Institute, University of Utah Hospitals & Clinics, Salt Lake City, Utah, USA David.stenehjem@hsc.utah.edu., Bellows BK; Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA SelectHealth, Salt Lake City, Utah, USA., Yager KM; Myriad Genetics, Inc., Salt Lake City, Utah, USA., Jones J; Myriad Genetics, Inc., Salt Lake City, Utah, USA., Kaldate R; Myriad Genetics, Inc., Salt Lake City, Utah, USA., Siebert U; Department of Public Health, Health Services Research and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology, Tyrol, Austria Area 4 Health Technology Assessment and Bioinformatics, Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Austria Department of Health Policy and Management, Center for Health Decision Science, Harvard School of Public Health, Boston, Massachusetts, USA Cardiovascular Research Program, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Brixner DI; Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA Program in Personalized Health, University of Utah, Salt Lake City, Utah, USA Department of Public Health, Health Services Research and Health Technology Assessment, University for Health Sciences, Medical Informatics and Technology, Tyrol, Austria Area 4 Health Technology Assessment and Bioinformatics, Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, Austria. |
